Graft materials containing ECM components, and methods for their manufacture
Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.
1. An extracellular matrix composition, comprising:
a dry collagenous powder comprising an extracellular matrix hydrolysate material, wherein said extracellular matrix hydrolysate material is effective to gel upon rehydration with an aqueous medium, and wherein said extracellular matrix hydrolysate material has been formed by digesting an extracellular matrix material with a hydrochloric acid solution containing an enzyme that digests the extracellular matrix material.
2. The composition of claim 1 , wherein the extracellular matrix hydrolysate material comprises components from vertebrate submucosa tissue.
3. The composition of claim 1 , wherein the extracellular matrix hydrolysate material has been prepared by a process comprising solubilizing an extracellular matrix composition with hydrochloric acid to produce a solubilized extracellular matrix material, and lyophilizing the solubilized extracellular matrix material to produce a lyophilized, solubilized extracellular matrix material that is capable of polymerizing upon rehydration.
4. A method of preparing a lyophilized extracellular matrix composition, comprising the steps of:
solubilizing an extracellular matrix composition with a hydrochloric acid solution containing an enzyme that digests the extracellular matrix composition to produce a solubilized extracellular matrix composition; and
lyophilizing the solubilized extracellular matrix composition from a solution having a pH of about 6 or below to produce a lyophilized, solubilized extracellular matrix composition.
5. The method of claim 4 , wherein the extracellular matrix composition that is solubilized comprises vertebrate submucosa tissue or basement membrane tissue.
6. An extracellular matrix composition prepared by a process comprising:
solubilizing an extracellular matrix composition with a hydrochloric acid solution containing an enzyme that digests the extracellular matrix composition, to form a solubilized composition of extracellular matrix components; and
lyophilizing the solubilized composition from a hydrochloric acid solution to produce a lyophilized, solubilized extracellular matrix composition wherein the lyophilized, solubilized composition, when dissolved at a concentration of 5 mg/ml in a 0.01 M hydrochloric acid solution, is capable of polymerization within 30 minutes.
7. The composition of claim 6 , wherein the enzyme is pepsin.
8. The composition of claim 6 , wherein the hydrochloric acid solution containing an enzyme that digests the extracellular matrix composition is a 0.01 M to 0.05 M hydrochloric acid solution containing an enzyme that digests the extracellular matrix composition.
9. The method of claim 4 , wherein said lyophilizing is conducted in the absence of acetic acid.
10. The method of claim 4 , wherein said enzyme is pepsin.
11. The method of claim 8 , wherein the hydrochloric acid is at a concentration of about 0.01 M.
12. A composition comprising a lyophilized extracellular matrix hydrolysate and an acid excipient comprising hydrochloric acid, wherein the lyophilized extracellular hydrolysate, when dissolved at a concentration of 5 mg/ml in a 0.01 M hydrochloric acid solution, is capable of polymerization within 30 minutes.
13. The composition of claim 12 wherein the lyophilized extracellular matrix hydrolysate is prepared by lyophilizing the extracellular matrix hydrolysate from a 0.01 M to 0.05 M hydrochloric acid solution.
14. The composition of claim 13 , wherein the lyophilized extracellular matrix hydrolysate is prepared by lyophilizing the extracellular matrix hydrolysate from an about 0.01 M hydrochloric acid solution.